Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003411 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003411 is a Phase 1 study that has completed, run by University of Pittsburgh.
The verdict
NCT00003411, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to treatment. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus motexafin gadolinium in treating patients with bile duct, gallbladder, or pancreatic cancer that cannot be removed surgically.
Interventions
- RADIATION radiation therapy
- DRUG motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2002-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003411
The ClinicalTrials.gov registry entry for NCT00003411 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00003411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003411 about?
NCT00003411 is a clinical study titled "Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to treatment. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus motexafin gadolinium in...
What is the current status of trial NCT00003411?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-11. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00003411?
The interventions under investigation include: radiation therapy (RADIATION), motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00003411?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.